miR-320在乳腺癌组织中的表达及临床意义

探讨miR-320在乳腺癌组织中的表达及其临床意义。方法采用逆转录聚合酶链反应法（RTPCR）检测108 例乳腺癌组织和对应癌旁正常组织中miR-320 表达,分析miR-320 表达与乳腺癌病理特征的相关性。结果乳腺癌组织中miR-320 表达水平低于正常乳腺组[（0.58±0.17）vs（1.05±0.21）]（p <0.05）。乳腺癌组织miR-320 表达水平与乳腺癌TNM分期及淋巴转移有关（p <0.05）;而miR-320 表达水平与年龄、绝经、病理类型、肿瘤大小、C-erbB-2 表达、增殖细胞核抗原（PCNA）表达、孕激素受体（PR）表达及雌激素受体（ER）表达无关（p >0.05）。结论miR-320 在乳腺癌组织中呈低表达,且其表达水平与乳腺癌发生发展密切相关,miR-320 可能是乳腺癌特异性诊断潜在标志物和治疗新靶点。

Expression and clinical significance of miR-320 in breast cancer

To evaluate the expression and clinical significance of miR-320 in breast cancer. Methods The expression of miR-320 in 108 cases of breast cancer tissues and normal breast tissue were detected by RT -PCR, and analyzed the correlation between expression of miR -320 in breast cancer,pathological feature and clinical prognosis. Results The miR-320 expression levels of breast cancer tissue were significantly lower than normal breast tissue [ (0.58 ±0.17) vs (1.05 ±0.21) ] ( p< 0.05). The miR-320 expression level was closely correlated with TNM staging and lymph node metastasis (p < 0.05), but the miR-320 expression level was no correlated with age, menopause, pathological type, tumor size, C -erbB -2 expression, PCNA expression, PR expression and ER expression (p > 0.05). Conclusions miR-320 is lowly expression in the breast cancer, and its expression level is closely related with occurrence and development of breast cancer.